Huntington's Disease (HD)
Patient Condition
Early Huntington's disease, CAG repetition number 44, mild chore-like movement, normal cognitive function, MoCA score 26. UHDRS TMS 13 points, TFC 13 points. Selected into the clinical trial of iPSC-derived neural stem cells.
Treatment Timeline
| Phase | Details | Date |
|---|---|---|
| Clinical trial screening and baseline assessment | ||
| iPSC neural stem cell transplantation | ||
| Postoperative recovery + immune management | ||
| Follow-up assessment and rehabilitation |
Treatment Outcome
| before | UHDRS TMS 13, TFC 13, MoCA 26, mild choreo-like movements, normal cognitive function |
|---|---|
| after | UHDRS TMS dropped to 7 points (6 points improvement), TFC maintained at 13 points, MoCA maintained at 26 points, choreo-like movements were significantly reduced, and PET showed improvement in metabolism in the transplanted area |
| highlight | iPSC neural stem cell transplantation is safe, improves brain metabolism in the transplanted area, and significantly reduces motor symptoms |